RT Journal Article
SR Electronic
T1 Comparative analysis of the outcomes of COVID-19 between patients infected with SARS-CoV-2 Omicron and Delta variants: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.30.22274532
DO 10.1101/2022.04.30.22274532
A1 Gunadi
A1 Mohamad Saifudin Hakim
A1 Hendra Wibawa
A1 Khanza Adzkia Vujira
A1 Dyah Ayu Puspitarani
A1 Endah Supriyati
A1 Ika Trisnawati
A1 Kristy Iskandar
A1 Riat El Khair
A1 Afiahayati
A1 Siswanto
A1 Yunika Puspadewi
A1 Irene
A1 Sri Handayani Irianingsih
A1 Edwin Widyanto Daniwijaya
A1 Dwi Aris Agung Nugrahaningsih
A1 Gita Christy Gabriela
A1 Esensi Tarian Geometri
A1 Laudria Stella Eryvinka
A1 Fadila Dyah Trie Utami
A1 Edita Mayda Devana
A1 Lanang Aditama
A1 Nathania Christi Putri Kinasih
A1 Verrell Christopher Amadeus
A1 Yekti Hediningsih
A1 Nur Rahmi Ananda
A1 Eggi Arguni
A1 Titik Nuryastuti
A1 Tri Wibawa
A1 the Yogyakarta-Central Java COVID-19 study group
YR 2022
UL http://medrxiv.org/content/early/2022/05/03/2022.04.30.22274532.abstract
AB Background The SARS-CoV-2 Omicron variant has replaced the previously dominant Delta variant because of high transmissibility. It is responsible for the current increase in the COVID-19 infectivity rate worldwide. However, studies on the impact of the Omicron variant on the severity of COVID-19 are still limited in developing countries. Here, we compared the outcomes of patients infected with SARS-CoV-2 Omicron and Delta variants and associated with prognostic factors, including age, sex, comorbidities, and smoking.Methods We involved 352 patients, 139 with the Omicron variant and 213 with the Delta variant. The whole-genome sequences of SARS-CoV-2 were conducted using the Illumina MiSeq next-generation sequencer.Results Ct value and mean age of COVID-19 patients were not significantly different between both groups (Delta: 20.35 ± 4.07 vs. Omicron: 20.62 ± 3.75; p=0.540; and Delta: 36.52 ± 21.24 vs. Omicron: 39.10 ± 21.24; p=0.266, respectively). Patients infected with Omicron and Delta variants showed similar hospitalization (p=0.433) and mortality rates (p=0.565). Multivariate analysis showed that older age (≥65 years) had higher risk for hospitalization (OR=3.67 [95% CI=1.22-10.94]; p=0.019) and fatalities (OR=3.93 [95% CI=1.35-11.42]; p=0.012). In addition, patients with cardiovascular disease had higher risk for hospitalization (OR=5.27 [95% CI=1.07-25.97]; p=0.041), whereas patients with diabetes revealed higher risk for fatalities (OR=9.39 [95% CI=3.30-26.72]; p=<0.001).Conclusions Our study shows that patients infected with Omicron and Delta variants reveal similar clinical outcomes, including hospitalization and mortality. In addition, our findings further confirm that older age, cardiovascular disease, and diabetes are strong prognostic factors for the outcomes of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Indonesian Ministry of Health and Dr. Sardjito Hospital funded our study. The funders had no role in study design, data collection, and analysis, decision to publish, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Medical and Health Research Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia (KE/FK/0563/EC/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.gisaid.org/